A moderately potent, but highly selective α2-adrenoceptor antagonist, the only reported selective antagonist at the α2B-adrenoceptor not having potent α1-adrenoceptor antagonist activity.
Sold with the permission of Roche Bioscience
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 280.75. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.56 mL||17.81 mL||35.62 mL|
|5 mM||0.71 mL||3.56 mL||7.12 mL|
|10 mM||0.36 mL||1.78 mL||3.56 mL|
|50 mM||0.07 mL||0.36 mL||0.71 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Michel et al (1990) Assessment of imiloxan as a selective α2B-adrenoceptor antagonist. Br.J.Pharmacol. 99 560 PMID: 1970500
If you know of a relevant reference for Imiloxan hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Imiloxan hydrochloride, supplier, selective, α2B-adrenoceptor, alpha2B-adrenoceptor, antagonists, α2b-adrenergic, alpha2b-adrenergic, a2-adrenoceptor, a2-adrenergic, Receptors, RS21361, RS, 21361, Adrenergic, Alpha-2, Receptors, Tocris Bioscience
Citations for Imiloxan hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Imiloxan hydrochloride. Do you know of a great paper that uses Imiloxan hydrochloride from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.